---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-039155"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:29:30.026866+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics reports FY2022 net loss of $112.7M; cash $28.8M, runway into Q3 2024

## Summary
- Cash and cash equivalents $28.8M at Dec 31, 2022, down from $53.1M; with $5.5M public offering, runway into Q3 2024.
- Q4 2022 net loss $2.4M ($0.92/share) vs $7.8M ($7.20/share) in Q4 2021; operating loss $2.7M vs $7.8M.
- Full year 2022 net loss $112.7M ($67.99/share) including $76M acquired IPR&D, vs $37.1M in 2021.
- R&D expenses fell to $0.5M in Q4 2022 from $4.5M as legacy trials wrapped; only one active trial vs six.
- ATRN-119 Phase 1/2a enrolling; ATRN-1051 IND filing expected by end of 2023; AACR abstract selected.

## SEC filing metadata
- accession: 0001104659-23-039155
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465923039155/0001104659-23-039155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465923039155/tm2310933d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-039155
- JSON: https://secwatch.observer/filing/0001104659-23-039155.json
- Plain text: https://secwatch.observer/filing/0001104659-23-039155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.